Giripladib - CAS 865200-20-0
Catalog number: 865200-20-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Giripladib is a Phospholipase A2 inhibitor. Treatment with Giripladib attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. Giripladib in combination with irradiation significantly reduced migration and proliferation in endothelial cells and induced cell death and attenuated invasion by tumor cells.
Publictions citing BOC Sciences Products
  • >> More
4-[3-[5-Chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]benzoic Acid; 4-(3-[5-Chloro-1-(diphenylmethyl)-2-[2-(((2-(trifluoromethyl)benzyl)sulfonyl)amino)ethyl]-1H-indole-3-yl]propyl)benzoic Acid; PLA 695
Soluble in DMSO
-20℃ Freezer
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Canonical SMILES:
Current Developer:
Originator Wyeth
1.Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
Thotala D1, Craft JM, Ferraro DJ, Kotipatruni RP, Bhave SR, Jaboin JJ, Hallahan DE. PLoS One. 2013 Jul 19;8(7):e69688. doi: 10.1371/journal.pone.0069688. Print 2013.
Lung cancer remains the leading cause of cancer deaths in the United States and the rest of the world. The advent of molecularly directed therapies holds promise for improvement in therapeutic efficacy. Cytosolic phospholipase A2 (cPLA2) is associated with tumor progression and radioresistance in mouse tumor models. Utilizing the cPLA2 specific inhibitor PLA-695, we determined if cPLA2 inhibition radiosensitizes non small cell lung cancer (NSCLC) cells and tumors. Treatment with PLA-695 attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. NSCLC cells (LLC and A549) co-cultured with endothelial cells (bEND3 and HUVEC) and pre-treated with PLA-695 showed radiosensitization. PLA-695 in combination with irradiation (IR) significantly reduced migration and proliferation in endothelial cells (HUVEC & bEND3) and induced cell death and attenuated invasion by tumor cells (LLC &A549). In a heterotopic tumor model, the combination of PLA-695 and radiation delayed growth in both LLC and A549 tumors.
2.Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation.
Duvernay MT1, Matafonov A2, Lindsley CW3, Hamm HE1. Biochemistry. 2015 Sep 15;54(36):5578-88. doi: 10.1021/acs.biochem.5b00549. Epub 2015 Sep 1.
With a newer, more selective and efficacious cytosolic phospholipase A2α (cPLA2α) inhibitor available, we revisited the role of cPLA2α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA2α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A2 receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA2α was responsible for this large component of PAR4- and GPVI-mediated platelet activation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phospholipase Products

CAS 356057-34-6 Darapladib

(CAS: 356057-34-6)

Darapladib (SB-480848) is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM.

CAS 865200-20-0 Giripladib

(CAS: 865200-20-0)

Giripladib is a Phospholipase A2 inhibitor. Treatment with Giripladib attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells...

ML 298 hydrochloride

ML 298 hydrochloride is a phospholipase D2 inhibitor with IC50 values are 355 for PLD2 and >20,000 nM for PLD1. It can decrease invasive migration in U87-MG gli...

CAS 899713-86-1 ML348

(CAS: 899713-86-1)

ML348, also known as CID 3238952 or SID 160654487, is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). It is 14-fold selective...

CAS 1130067-06-9 VU 0155069

VU 0155069
(CAS: 1130067-06-9)

VU 0155069 is a potent and selective phospholipase D1 (PLD1) inhibitor (IC50 = 46 and 933 nM for PLD1 and PLD2, respectively). VU 0155069 has been shown to inhi...

CAS 83373-60-8 D609

(CAS: 83373-60-8)

D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor and is antiviral and antitumor agent. It suppresses LPS- and IF...

CAS 1096687-52-3 SPK-601

(CAS: 1096687-52-3)

SPK-601 is a potent phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor,a useful antimicrobial agent.

(CAS: 221914-85-8)

BMS-229724 is a selective tight-binding inhibitor of cytosolic phospholipase A2 (cPLA2) in that it did not inhibit secreted phospholipase A2 in vitro, nor phosp...

CAS 69-05-6 Quinacrine hydrochloride

Quinacrine hydrochloride
(CAS: 69-05-6)

Quinacrine dihydrochloride is the dihydrochloride salt of the 9-aminoacridine derivative quinacrine with potential antineoplastic and antiparasitic activities. ...

CAS 200933-14-8 m-3M3FBS

(CAS: 200933-14-8)

m-3M3FBS is a direct activator of phospholipase C (PLC) that stimulates the increase in cytoplasmic calcium, inositol phosphate formation and superoxide generat...

CAS 1244640-48-9 VU 0364739 hydrochloride

VU 0364739 hydrochloride
(CAS: 1244640-48-9)

VU 0364739 hydrochloride is a potent and selective phospholipase D2 (PLD2) inhibitor (IC50 = 20 nM), displaying 75-fold selectivity over PLD1 (IC50 = 1500 nM).

CAS 141022-99-3 PACOCF3

(CAS: 141022-99-3)

PTK is an analog of palmitic acid. It is a phospholipase A2 inhibitor.

CAS 112648-68-7 U-73122

(CAS: 112648-68-7)

U-73122 is a phospholipase C inhibitor originated by Pharmacia Corporation and IC 50 value is 1.0-2.1 μM in neutrophils and human platelets. U-73122 can be used...

CAS 1233706-88-1 CAY10650

(CAS: 1233706-88-1)

Cytosolic phospholipase A2α (cPLA2α) specifically catalyzes the hydrolysis of arachidonic acid from the sn-2-ester position of membrane phospholipids, playing a...

CAS 221632-26-4 OBAA

(CAS: 221632-26-4)

OBAA is a phospholipase A2 inhibitor with IC50 value of 70 nM. It can reduce bronchospasm in guinea pigs in vivo.

CAS 145843-69-2 D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt

(CAS: 145843-69-2)

D-myo-Inositol-1,3,4,5-tetrakisphosphate, octapotassium salt is the octapotassium salt of D-myo-Inositol-1,3,4,5-tetrakisphosphate, which is the phosphorylation...

(CAS: 107889-32-7)

LY-178002 is a phospholipase A2 inhibitor. It also inhibits leukotriene B4 production.

CAS 172732-68-2 Varespladib

(CAS: 172732-68-2)

Varespladib is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2). The compound Varespladib inhibits both human and mouse sPLA2 group IIA, V...

CAS 1404456-53-6 GSK2830371

(CAS: 1404456-53-6)

GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM.

CAS 144337-18-8 YM 26734

YM 26734
(CAS: 144337-18-8)

YM 26734 is a competitive inhibitor of secretory phospholipase A2 (sPLA2) with a broad inhibitory profile to several sPLA2s (IC50 = 0.2, 1, 1, 1 and 3 μM for sP...

Chemical Structure

CAS 865200-20-0 Giripladib

Quick Inquiry

Verification code

Featured Items